REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1583116
This article is part of the Research TopicCurrent trends in Immunotherapy: From Monoclonal Antibodies to CAR-T CellsView all 4 articles
CAR-T cell Therapy Clinical Trials: Global Progress, Challenges, and Future Directions from ClinicalTrials.gov Insights
Provisionally accepted
Liya Cao1
Yue Zhao1Yang Chen2
Pan Ma1Jiang-Chuan Xie1Xin-Mei Pan1Xin Zhang1
Yongchuan Chen1*
Qian Wang1*Lin-li Xie1*- 1Department of Pharmacy, The first affiliated hospital of army medical university, Chongqing, China
- 2Chongqing Emergency Medical Center, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chimeric antigen receptor T (CAR-T) cell therapy has undergone vigorous development in recent years, yet it still faces significant challenges and difficulties in its clinical application and further development. A systematic synthesis of global trends in CAR-T clinical trials is essential to identify knowledge gaps, optimize treatment strategies, and guide future research directions. This review analyzed 1,580 CAR-T clinical trials registered at ClinicalTrials.gov as of April 2024, and extracted characteristic data in multiple dimensions, including target specificity, treatment indication, and development stage etc. The transparency of trial outcomes was assessed by validation with articles published in PubMed/ Google Scholar.Additionally, it is complemented by investigator surveys assessing to barriers to CAR-T development, prospects, and recommendations.In April 2024, we retrieved data from ClinicalTrials.gov to identify relevant CAR-T studies. To ensure comprehensive coverage, the research team employed the
Keywords: Chimeric antigen receptor T-cell, clinical trials, Clinicaltrials.gov, hematological malignancies, solid tumors, publication following search queries: Condition/disease or Intervention/treatment: "CAR T", "Chimeric Antigen Receptor", "CAR T cell"
Received: 25 Feb 2025; Accepted: 29 Apr 2025.
Copyright: © 2025 Cao, Zhao, Chen, Ma, Xie, Pan, Zhang, Chen, Wang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yongchuan Chen, Department of Pharmacy, The first affiliated hospital of army medical university, Chongqing, China
Qian Wang, Department of Pharmacy, The first affiliated hospital of army medical university, Chongqing, China
Lin-li Xie, Department of Pharmacy, The first affiliated hospital of army medical university, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.